AbbVie inked a sizable $700 million upfront deal for rights to ISB-2001, an early-stage trispecific antibody developed by IGI Therapeutics designed to bind three targets on multiple myeloma cells. The antibody engages CD3, BCMA, and CD38, showing promising Phase 1 results with a favorable safety profile. AbbVie's acquisition includes development and commercial milestones worth up to $1.23 billion, expanding its pipeline into multispecific modalities with potential application across oncology and autoimmune indications.